INTRODUCTION {#s1}
============

Malignant gliomas rank among the most prevalent primary intracranial neoplasms in adults \[[@R1]\], with an incidence of 80%. \[[@R2]\] Based on the the World Health Organization (WHO) criteria \[[@R3]\], grade IV glioblastoma multiforme (GBM) accounts for almost 65% of all the gliomas. The average survival is poor and age-dependent.\[[@R4]\] Anaplastic glioma (grade III) is a diverse group of malignancies comprising anaplastic astrocytoma (AA), anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO). It is less frequently diagnosed and is associated with better prognosis compared with grade IV glioblastoma, despite shared molecular features and poor outcomes in the elderly.\[[@R5], [@R6]\]

Surgical resection or biopsy, and involved-field radiotherapy are indicated for the treatment of glioblastomas or anaplastic gliomas. Radiation and chemotherapy with temozolomide (TMZ) is the standard of care for patients with glioblastomas.\[[@R7]\]

The prognosis of grade II - IV malignant glioma is largely dependent on age. Recent studies have mainly focused on older patients and suggest that the benefit of treatment is reduced with age. \[[@R8]\] Cranial irradiation is associated with an increased risk of cognitive impairment.\[[@R9]\] Further, older patients are poorly tolerant to radiotherapy combined with TMZ.\[[@R10]\] Other studies suggest that older patients with a good performance status benefit from radiotherapy \[[@R11]\] and possibly from chemotherapy.\[[@R12]\] In addition, the ANOCEF Phase II results also indicated that TMZ was safe in elderly patients with GBM and poor KPS.\[[@R13]\] Conversely, few studies have focused on the treatment and survival of younger adults (age \< 50 years).

In this study, we summarized the clinical management and evaluated the role of age in clinical outcomes of patients diagnosed with grade III and IV gliomas. We determined the clinical efficacy of treatment across different ages, especially younger adults with advanced gliomas in a large population in the Chinese Glioma Genome Atlas (CGGA).

RESULTS {#s2}
=======

Patients {#s2_1}
--------

In this study, we analyzed 726 patients diagnosed with advanced (WHO grade III and IV) gliomas from the Chinese Glioma Genome Atlas (CGGA).

Patient demographics are listed in Table [1](#T1){ref-type="table"}.The study population included a higher number of males (61%) than females. The study included 264 older patients (OP) and 462 younger patients (YP). The median age of OP was 58 years (ranging from 50 to 83). The median age of YP was 39 years (ranging from 18-49). Sixty percent of all patients had a preoperative KPS ≥ 80, including 53% in OP and 64% in YP, respectively. The histopathological diagnosis of patients treated surgically was established by two neuropathologists according to the 2016 WHO classification system. Grade III anaplastic glioma in 81 patients (31%) of the OP group, included 20 patients (8%) with anaplastic astrocytoma, 16 (6%) with anaplastic oligodendroglioma, and 45 (17%) with oligoastrocytoma. Grade IV GBM was found in 183 patients of the OP (69%) group. In YP, Grade III anaplastic glioma was detected in 201 patients (44%), including 55 (12%) with anaplastic astrocytoma, 35 (8%) with anaplastic oligodendroglioma, and 111 (24%) with oligoastrocytoma. Grade IV GBM was found in 261 patients in YP (56%).

###### Baseline patient characteristics

  --------------------------------------------------------------------------------------------------------------------------------------
                                                      Total (*n*=726,%)   Age≥50 (*n*=264, 36%)   Age\<50 (*n*=462, 64%)   *P* value
  --------------------------- ----------------------- ------------------- ----------------------- ------------------------ -------------
  Age                         Median (range)          45 (18-83)          58 (50-83)              39 (18-49)               

  Gender                      Male                    443 (61)            161 (61)                282 (61)                 P=0.9885

  Female                      283 (39)                103 (39)            180 (39)                                         

  Presenting symptoms         Increased ICP           294 (40)            110 (42)                184 (40)                 *P*\<0.0001

  Epilepsy                    129 (18)                31 (12)             98 (21)                                          

  Neurologic deficit          204 (28)                105 (40)            99 (21)                                          

  KPS score                   Preoperative KPS≥80     437 (60)            140 (53)                297 (64)                 *P*=0.0029

  Preoperative KPS\<80        289 (40)                124 (47)            165 (36)                                         

  Pathological type           AA                      75 (10)             20 (8)                  55 (12)                  *P*=0.0076

  AO                          51 (7)                  16 (6)              35 (8)                                           

  AOA                         156 (21)                45 (17)             111 (24)                                         

  GBM                         444 (61)                183 (69)            261 (56)                                         

  Side of tumor               Left                    334 (46)            119 (45)                215 (47)                 *P*=0.8060

  Right                       333 (46)                125 (47)            208 (45)                                         

  Bilateral                   59 (8)                  20 (8)              39 (8)                                           

  Tumor location\             Frontal lobe            333 (46)            102 (39)                231 (50)                 *P*=0.0294
  (involved)                                                                                                               

  Temporal lobe               264 (36)                103 (39)            161 (35)                                         

  Parietal lobe               114 (16)                47 (18)             67 (15)                                          

  Occipital lobe              74 (10)                 35 (13)             39 (8)                                           

  Insular lobe                80 (11)                 27 (10)             53 (11)                                          

  Resection                   Gross total resection   424 (58)            154 (58)                270 (58)                 *P*=0.9773

  Subtotal                    302 (42)                110 (42)            192 (4)                                          

  Postoperative Treatment     RT plus TMZ             352 (48)            131 (50)                221 (48)                 *P*=0.7597

  RT                          90 (12)                 36 (14)             54 (12)                                          

  TMZ                         38 (5)                  11 (4)              27 (6)                                           

  Supportive Treatment        68 (9)                  25 (9)              43 (9)                                           

  NA                          178 (25)                61 (23)             117 (25)                                         

  IDH1 mutation               Mutation                184 (25)            34 (13)                 150 (32)                 *P*\<0.0001

  Wildtype                    470 (65)                205 (78)            265 (57)                                         

  NA                          72 (10)                 25 (9)              47 (10)                                          

  1p LOH                      Deletion                43 (6)              13 (5)                  30 (6)                   *P*=0.6526

  No deletion                 430 (59)                156 (59)            274 (59)                                         

  NA                          253 (35)                95 (36)             158 (34)                                         

  19q LOH                     Deletion                46 (6)              12 (5)                  34 (7)                   *P*=0.3193

  No deletion                 427 (59)                157 (59)            270 (58)                                         

  NA                          253 (35)                95 (36)             158 (34)                                         

  1p/19q codeletion           Deletion                36 (5)              8 (3)                   28 (6)                   *P*= 0.1913

  No deletion                 437 (60)                161 (61)            276 (60)                                         

  NA                          253 (35)                95 (36)             158 (34)                                         

  MGMT promoter methylation   Methylated              236 (32)            88 (33)                 148 (32)                 *P*\<0.0001

  Not methylated              229 (32)                105 (40)            124 (27)                                         

  NA                          261 (36)                71 (27)             190 (41)                                         
  --------------------------------------------------------------------------------------------------------------------------------------

The standard treatment for malignant gliomas consists of surgery, postoperative radiotherapy, combined with adjuvant TMZ chemotherapy. Surgical resection is the first choice. Gross total resection was conducted in 424 patients (58 %) including 154 (58%) OP and 270 (58%) YP cases, respectively. In the OP group, 131 (50 %) patients were treated with postoperative radiotherapy, and TMZ chemotherapy (RT+TMZ), 36 (14%) underwent postoperative radiotherapy alone (RT), 11 (4%) received postoperative TMZ chemotherapy alone (TMZ) and 25 (9%) were managed with supportive treatment. In the YP group, 221 (48%) were treated with postoperative radiotherapy and TMZ chemotherapy (RT+TMZ), 54 (12%) received postoperative radiotherapy alone (RT), 27 (6%) received postoperative TMZ chemotherapy alone (RT) and 43 (9%) were managed with supportive treatment (Table [1](#T1){ref-type="table"}).

Genetic aberrations {#s2_2}
-------------------

Patients with adequate tumor specimens were analyzed for genetic changes including isocitrate dehydrogenase 1 (*IDH1*) mutations, 1p/19q loss of heterozygosity (LOH) and promoter methylation of O6-methylguanine-DNA methyltransferase (MGMT). The number and frequency of alterations in each age group are listed in Table [1](#T1){ref-type="table"}. In the OP group, 35 tumors (13 %) harbored *IDH1* mutations, 34 tumors (5 %) carried LOH on 1p, 12 cases (5 %) showed LOH on 19q, 8 cases (3 %) exhibited 1p/19q co-deletion and 88 tumors (33 %) revealed *MGMT* promoter methylation. In the YP group, *IDH1* mutations were detected in 150 cases (32 %), much higher than in OP (P \< 0.0001). The other genetic alterations in the YP group were as follows: LOH involving 1p in 30 cases (6 %), LOH involving 19q in 34 cases (7 %), 1p/19q co-deletions in 28 cases (6 %) and MGMT promoter methylation in 148 tumors (32 %).

Survival {#s2_3}
--------

The 243 patients with anaplastic glioma (86%) and 406 patients with GBM (91%) were followed up. Among the two age-specific subgroups with advanced gliomas, the prognosis of YP was more favorable than in OP in terms of overall survival (OS) and progression-free survival (PFS) (P \< 0.001; Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). The median OS of patients in the OP group treated with RT plus TMZ, RT alone and supportive treatment was 17.9, 12.9 and 10.5 months, respectively. In the YP group, the median OS of patients treated with RT combined with TMZ, RT alone and supportive treatment was 25.8, 21.3 and 11.1 months, respectively, which were significantly longer than in the OP group. In the OP group, the median PFS with RT plus TMZ, RT alone and supportive treatment was 12.3, 8.4 and 9.3 months, respectively. In the YP group, the median PFS of the above three groups was 17.3, 13.6 and 6.0 months, respectively. The OS and PFS of OP and YP groups exposed to different treatments are listed in Table [2](#T2){ref-type="table"}.

![Kaplan--Meier analysis of overall survival (OS) and progression-free survival (PFS) based on age Kaplan--Meier curves showed better prognosis in patients aged \< 50 compared with older patients (age ≥ 50) in terms of OS (**A**) and PFS (**B**)](oncotarget-07-80091-g001){#F1}

###### First-line therapy of patients according to age stratification

                       Patients with Age ≥ 50   Patients with Age \< 50                        
  -------------------- ------------------------ ------------------------- ------ ------ ------ ------
  No. of patients      131                      36                        25     221    54     43
  Median OS (month)    17.9                     12.9                      10.5   25.8   21.3   11.1
   at 6-month (%)      92                       86                        68     92     73     65
   at 1-year (%)       62                       48                        41     79     59     40
   at 3-year (%)       29                       15                        7      37     41     17
   at 5-year (%)       19                       8                         NA     28     33     11
  Median PFS (month)   12.3                     8.4                       9.3    17.3   13.6   6
   at 6-month (%)      77                       51                        59     81     64     50
   at 1-year (%)       48                       27                        32     62     50     29
   at 3-year (%)       20                       12                        7      30     34     11
   at 5-year (%)       17                       8                         NA     25     29     NA

Survival correlated with age, tumor grade and therapeutic strategy {#s2_4}
------------------------------------------------------------------

Kaplan--Meier analysis of OS and PFS in the different age groups is presented in Figure [2](#F2){ref-type="fig"}. In the OP, both OS and PFS were significantly longer in the RT plus TMZ group than in RT group (P = 0.013, Figure [2A](#F2){ref-type="fig"} and P = 0.007, Figure [2B](#F2){ref-type="fig"}). By contrast, no significant benefit in OS and PFS was observed in the YP group managed with RT plus TMZ chemotherapy (P = 0.212, Figure [2C](#F2){ref-type="fig"} and P = 0.499, Figure [2D](#F2){ref-type="fig"}).

![Kaplan--Meier analysis of OS and PFS based on treatment in OP and YP groups\
Kaplan--Meier curves show significant differences in the OP group in both OS (**A**) and PFS (**B**) following treatment with RT plus TMZ and RT alone. By contrast, in the YP group, no significant differences in OS (**C**) or PFS (**D**) were observed with RT plus TMZ.](oncotarget-07-80091-g002){#F2}

In the OP group of patients with GBM, a favorable OS and PFS was observed among patients treated postoperatively with RT plus TMZ (P = 0.035, Figure [3A](#F3){ref-type="fig"} and P = 0.013, Figure [3B](#F3){ref-type="fig"}). In the YP group diagnosed with GBM, patients assigned to RT and TMZ exhibited significantly longer OS and PFS compared with those administered RT alone (P \< 0.001, Figure [3C](#F3){ref-type="fig"} and P \< 0.001, Figure [3D](#F3){ref-type="fig"}).

![Kaplan--Meier analysis of OS and PFS according to tumor grade and treatment assignment in OP and YP groups\
OP patients with GBM treated postoperatively with RT plus TMZ showed improved OS (**A**) and PFS (**B**). YP patients with GBM assigned to RT plus TMZ also showed significantly longer OS (**C**) and PFS (**D**) compared with those treated with RT alone. OP patients with anaplastic gliomas assigned to RT plus TMZ exhibited significantly longer OS (**E**) and PFS (**F**) compared with patients treated with RT alone. By contrast, in YP patients with WHO grade III gliomas, treatment with RT plus TMZ yielded no survival benefit when compared with treatment using RT alone, in terms of both OS (**G**) and PFS (**H**).](oncotarget-07-80091-g003){#F3}

In the OP group diagnosed with anaplastic gliomas (WHO grade III), patients treated with RT plus TMZ showed significantly longer OS and PFS compared with those treated with RT alone (P = 0.039, Figure [3E](#F3){ref-type="fig"} and P=0.045, Figure [3F](#F3){ref-type="fig"}). By contrast, no survival advantage was found in the YP group diagnosed with WHO grade III gliomas when treated with RT plus TMZ compared with RT alone in terms of OS (P = 0.429, Figure [3G](#F3){ref-type="fig"}) and PFS (P = 0.269, Figure [3H](#F3){ref-type="fig"}).

Survival correlated with genetic mutations and therapeutic strategies {#s2_5}
---------------------------------------------------------------------

To determine the correlation between patient survival, and genetic alterations and therapeutic strategies, we analyzed *IDH1* mutations, 1p/19q co-deletions and *MGMT* promoter methylation. Table [3](#T3){ref-type="table"} summarizes the genetic changes in each subgroup (age \< 50 or ≥ 50, RT+TMZ or RT alone). No significant differences were found among the different treatment groups in terms of genetic alterations in both anaplastic gliomas and GBMs. In all the patients in the OP and YP groups diagnosed with GBMs, the optimal survival benefit was always found among patients treated with RT combined with TMZ regardless of MGMT promoter methylation. In the YP group with anaplastic gliomas, no survival benefit was observed with RT plus TMZ compared with RT alone, independent of genetic alterations. We also performed Kaplan-Meier analysis of OS and PFS based on genetic changes in the different age groups ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}).

###### Comparison of genetic alternation between different subgroups according to age and treatment

  N (%)            Anaplastic glioma   GBM                                                                                              
  ---------------- ------------------- --------- --------- --------- --------- --------- --------- --------- -------- --------- ------- --------
  mIDH             11 (20)             4 (7)     0.91      42 (32)   20 (15)   0.0855    7 (7)     1 (1)     0.5642   22 (18)   4 (3)   0.8755
  wtIDH            28 (52)             11 (20)   55 (42)   13 (10)   75 (73)   20 (19)   80 (66)   16 (13)                              
  methMGMT         23 (44)             9 (17)    0.8846    63 (54)   19 (16)   0.3489    20 (23)   9 (10)    0.2232   33 (32)   5 (5)   0.2743
  unmethMGMT       14 (27)             6 (12)    24 (21)   11 (9)    46 (53)   11 (13)   50 (49)   14 (14)                              
  codele1p/19q     3 (8)               2 (5)     0.5587    14 (14)   3 (3)     0.3021                                                   
  uncodele1p/19q   24 (63)             9 (24)    56 (58)   24 (25)                                                                      

Multivariate analysis {#s2_6}
---------------------

Multivariate analysis of OS and PFS included age, KPS, tumor grade, extent of resection, radiotherapy, TMZ chemotherapy, IDH1 mutation and *MGMT* promoter methylation (Figure [4](#F4){ref-type="fig"}).

![Cox regression analysis of variables related to OS and PFS in OP (**A** and **B**) and YP (**C** and **D**)\
Cox model for age (age ≤ 70 vs. \> 70 for OP and age ≤ 40 vs. \> 40 for YP), KPS ≥ 80 vs. \< 80, Grade III vs. GBM, gross total resection vs. no gross total resection, radiotherapy vs. no radiotherapy, TMZ chemotherapy vs. no TMZ chemotherapy, *IDH1* mutation vs. no *IDH1* mutation, *MGMT* promoter methylation vs. no *MGMT* promoter methylation.](oncotarget-07-80091-g004){#F4}

In the OP group with advanced gliomas, age ≤ 70 (P = 0.018), higher KPS score (KPS ≥ 80, P \< 0.001) and MGMT promoter methylation (P = 0.015) were significantly associated with OS in multivariate Cox analysis (Figure [4A](#F4){ref-type="fig"}). A higher KPS (KPS ≥ 80, P \< 0.001) and gene methylation (P = 0.006) were significantly associated with PFS (Figure [4B](#F4){ref-type="fig"}). In the YP group diagnosed with advanced gliomas, higher KPS (KPS ≥ 80, P \< 0.001), lower WHO grade (grade III, P \< 0.001) and TMZ chemotherapy (P = 0.017) were independent risk factors for OS (Figure [4C](#F4){ref-type="fig"}). The prognostic risk factors for PFS included higher KPS (KPS ≥ 80, P \< 0.001), lower WHO grade (grade III, P \< 0.001), TMZ chemotherapy (P = 0.031) and *IDH1* mutation (P = 0.027) (Figure [4D](#F4){ref-type="fig"}).

DISCUSSION {#s3}
==========

Advances in radiotherapy \[[@R14], [@R15]\] and treatment with nitrosourea-based interventions led to limited therapeutic success.\[[@R16]\] Temozolomide, \[[@R17]\] first used for the treatment of recurrent malignant gliomas, appeared promising for recurrent WHO grade III gliomas. However, the effective response of glioblastomas ranged between 5% and 8%.\[[@R18], [@R19]\] The role of TMZ chemotherapy was undefined \[[@R20]\] until the EORTC 26981 trial was published. The trial found a significantly prolonged survival in GBM patients treated with adjuvant TMZ chemotherapy.\[[@R7]\]

Since 2005, patients diagnosed with WHO grade III and IV gliomas were recommended TMZ combined with RT. However, patients are unable to afford TMZ therapy due to lack of insurance coverage.\[[@R21]\] We, therefore, analyzed patients exposed to the combination therapyand RT alone. We found a higher efficacy of TMZ in older patients than in younger patients.In the current study, we validated previous evidence suggesting that the combination of RT and TMZ enhanced the survival of GBM patients compared with RT alone, despite age stratification.\[[@R7]\] In contrast, younger patients with anaplastic gliomas (WHO grade III) manifested greater survival following treatment with RT combined with TMZ compared with RT alone.

Age is an independent prognostic factor in grade II-IV malignant glioma. Compared with aged and elderly patients, younger adults show a relatively better prognosis as well as improved general condition. They also exhibit greater tolerance to surgical resection. Anaplastic glioma or glioblastoma patients carrying mutant *IDH1* or *IDH2* are significantly younger than those harboring wild-type *IDH1* and *IDH2*.\[[@R22], [@R23]\] Our findings are consistent with these studies in that the frequency of *IDH* mutations was low in patients aged above 50 (13% vs. 32%, P \< 0.0001). The NOA-04 trial and validation cohorts in NOA-08 and the German Glioma Network indicated that methylation of *MGMT* promoter improved outcomes in patients carrying wild-type *IDH*.\[[@R24]\] However, the present study offered no definitive evidence suggesting that *IDH* mutations increased the benefit of adjuvant TMZ chemotherapy. A comparison of genetic alterations across different subgroups according to age and treatment, yielded no significant differences in anaplastic gliomas and GBMs. This finding suggests that age was one of the prognostic risk factors in patients treated with adjuvant TMZ chemotherapy for anaplastic glioma.

Age, extent of resection and tumor grade are established prognostic factors for gliomas. According to clinical practice guidelines \[[@R25], [@R26]\], both tumor grade and extent of resection are primary risk factors for therapeutic decision-making. However, it remains unclear whether age is an independent prognostic factor in malignant gliomas, especially in younger adults. In this study, we mainly focused on younger adults diagnosed with high-grade gliomas, in an effort to correlate survival with treatment in age-specific subgroups. In spite of the limitations of this retrospective study, we demonstrated no survival benefit in younger adults aged under 50, with anaplastic gliomas treated with RT combined with TMZ compared with RT alone. Conversely, older adults with anaplastic gliomas and GBMs may benefit from RT combined with TMZ treatment. Furthermore, the specific genetic alterations were not prognostic indicators for TMZ chemotherapy in any patients.

Our findings may trigger discussion involving younger adults diagnosed with anaplastic glioma in the combination therapy arm. The positive outcome indicated that RT or TMZ alone was adequate for younger patients diagnosed with anaplastic glioma, which warrants further validation in prospective randomized studies

MATERIALS AND METHODS {#s4}
=====================

Patients\' clinical demographics {#s4_1}
--------------------------------

Adult patients aged at least 18 years and diagnosed with advanced gliomas (WHO III-IV: AA, AO, AOA and GBM) in the Chinese Glioma Genome Atlas (CGGA) were retrospectively studied. All patients were managed surgically, followed by postoperative radiotherapy, and concomitant and/or adjuvant TMZ chemotherapy at the Glioma Treatment Center of Beijing Tiantan Hospital and Beijing Sanbo Brain Hospital, from October 2004 to July 2012. The study was approved by the hospital ethics committees. All the patients provided written informed consent. The histological diagnosis was validated by two independent neuropathologists and graded according to the 2016 WHO criteria.\[[@R3]\] Patients\' clinical records were reviewed for age at diagnosis, sex, presenting symptoms, preoperative Karnofsky performance status (KPS) score, and surgical status. Patients at least 50 years of age were defined as Older Patients (OP) while those under 50 years were categorized as Younger Patients (YP). Overall survival (OS) was defined as the period starting from operation until death. OS data were primarily collected during patients\' visit to the clinic and via phone interviews with patients and their relatives. Progression-free survival (PFS) was recorded starting with surgery until radiographic progression. The exclusion criteria were: patients lost to follow-up or death from secondary diseases.

Treatment {#s4_2}
---------

Standard care comprised surgery, postoperative adjuvant radiotherapy, and concomitant and adjuvant TMZ chemotherapy. The primary goal of surgery was maximal tumor bulk resection excluding the cortex. MRI findings were used to determine tumor characteristics and the extent of resection within 48 h post-surgery. Abnormal preoperative fluid-attenuated inversion recovery (FLAIR) signals were used to compare the extent of resection (gross or subtotal) based on neuroradiologist reports.\[[@R27]\] The extent of resection was independently determined by two experienced radiologists, who were blinded to the clinical data. The initial postoperative interventions were classified into postoperative radiotherapy combined with concomitant and adjuvant TMZ chemotherapy (RT/TMZ→TMZ) or postoperative radiotherapy alone (RT) for patients with GBMs; postoperative radiotherapy in addition to adjuvant TMZ chemotherapy (RT→TMZ), adjuvant TMZ chemotherapy alone (TMZ) or postoperative radiotherapy alone (RT) for patients with anaplastic gliomas. Routine postoperative adjuvant radiotherapy was administered to patients within four weeks after surgery. The total dose of 54-60 Gy was administered over 30 days, in daily doses of 1.8-2 Gy, and 5 fractions were administered each week. Concomitant chemotherapy comprised a daily dose of TMZ (75 mg/m2) over seven days weekly starting with the first until the last day of radiotherapy, for a maximum of 49 days. After a four-week hiatus, patients were administered up to six cycles of adjuvant oral TMZ (150--200 mg/m2) for 5 days every 28 days. The chemotherapy regimen included a total of 6 cycles in the absence of disease progression or irreversible hematological toxicity.

Molecular evaluation {#s4_3}
--------------------

Tumor tissue samples were resected surgically before starting radio- or chemotherapy. The tissue specimens were snap-frozen and stored in liquid nitrogen until further use.

Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen). The DNA samples were analyzed using the Nano-Drop ND-1000 spectrophotometer (NanoDrop Technologies, Houston, TX). The sample specimems were analyzed for *IDH1* mutations (R132 site, DNA pyro-sequencing), *MGMT* promoter methylation (DNA pyro-sequencing) and 1p/19q co-deletion (fluorescence *in situ* hybridization).\[[@R28], [@R29]\]

Survival and follow-up {#s4_4}
----------------------

Survival was monitored clinically during patient visits and via telephone interviews. Patients who were biopsied were excluded from this study. The baseline examination included magnetic resonance imaging (MRI), total blood counts, hematological tests, and physical examinations. During radiotherapy (with or without TMZ), patients were monitored weekly. Comprehensive investigations included physical and radiological assessments 21 to 28 days after radiotherapy and every 3 months subsequently. Adjuvant TMZ therapy included monthly clinical evaluation and comprehensive assessment toward the end of the third and sixth cycles. Tumor progression was defined by a 25% increase in tumor size, new lesions, or an increased need for corticosteroid therapy.\[[@R30]\]

Statistical analyses {#s4_5}
--------------------

SPSS 13.0 software (USA) was used to analyze the data. The differences in clinicopathological characteristics between older and younger adult patients were evaluated with X2 test. OS and PFS were estimated using Kaplan--Meier analysis and compared with two-sided log-rank test. Cox (proportional-hazards) regression analysis was used to assess the prognostic role of the clinicopathological factors and statistically significant treatment protocols based on univariate testing. A P-value \< 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIAL {#s5}
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